Skip to content
drillr.ai

PCVX

Vaxcyte, Inc.

NASDAQ · USHealthcareBiotechnology
$55.50-1.25%

Price as of Jul 20, 2026

PCVX news

Vaxcyte, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Vaxcyte to Participate in Upcoming Investor Conferences

    SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: * Leerink Partners Therapeutics Forum, July 14-15, 2026: Meetings will take place on Wednesday, July 15. * BTIG Virtual Biotechnology Conference, July 28-29, 2026: Meetings will take place on Tuesday, July 28. About Vaxcyte  Vaxcyte is a vac

    Globe Newswire ·

  2. Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

    First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Si

    Globe Newswire ·

  3. Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

    OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive(®) (PCV21) and Prevnar 20(®) (PCV20), the Current Standard-of-Care PCVs Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Phase 3 Study Expected in Fourth Quarter of 2026 OPUS-2 Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine Designed

    Globe Newswire ·

  4. Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

    Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and Immunoglobulin G Immune Responses for All 31 Serotypes and Was Observed to be Well Tolerated with a Safety Profile Similar to Prevnar 20®

    Globe Newswire ·